BEP

Testicular germ cell tumors (GCT): Standard first-line treatment for good-risk and intermediate/poor-risk metastatic GCT. Also used in ovarian GCT and extragonadal GCT.

BEP (standard, every 21 days):
Bleomycin 30 units IV push on Days 1, 8, and 15.
Etoposide 100 mg/m² IV over 60 minutes on Days 1–5.
Cisplatin 20 mg/m² IV over 30–60 minutes on Days 1–5.
Cycles: 3 cycles for good-risk disease; 4 cycles for intermediate/poor-risk.
Aggressive IV hydration required with cisplatin. Antiemetics essential.

• Pulmonary Toxicity (Bleomycin): Bleomycin-induced pneumonitis and pulmonary fibrosis. Limit cumulative bleomycin dose. Monitor for dyspnea; stop bleomycin if pulmonary toxicity suspected.
• Renal Toxicity (Cisplatin): Cisplatin nephrotoxicity. Aggressive IV hydration required. Monitor SCr and electrolytes.
• Neurotoxicity (Cisplatin): Peripheral neuropathy and ototoxicity are cumulative.
• Myelosuppression: Etoposide and cisplatin cause neutropenia and thrombocytopenia. Monitor CBCs.
• Raynaud's Phenomenon: Bleomycin-associated vascular toxicity; can persist long-term.
• Embryo-Fetal Toxicity: All three agents are teratogenic.

Nausea/Vomiting (90%), Myelosuppression (60%), Alopecia (65%), Peripheral neuropathy (40%), Pulmonary toxicity (10%), Raynaud's phenomenon (10%), Ototoxicity (25%), Fatigue (70%)

Adverse reaction frequencies reflect combination regimen data. Consult individual prescribing information for complete details.

BEP achieves synergistic cytotoxicity through three mechanisms: Bleomycin causes DNA single- and double-strand breaks via oxidative damage and free radical generation. Etoposide inhibits topoisomerase II, causing lethal double-strand DNA breaks. Cisplatin forms intrastrand and interstrand DNA cross-links, inhibiting replication and transcription. The combination is highly effective in rapidly dividing germ cell tumors.

• Indiana University BEP trials — Foundational BEP regimen development in metastatic testicular GCT. Multiple Phase III studies establishing BEP as standard of care.
  📄 Primary Publication ↗
• EORTC 30941 — BEP vs other regimens in good-risk GCT. Confirmed 3 cycles BEP as standard.
  📄 Primary Publication ↗